# Developmental Funds

> **NIH CA P30** · WISTAR INSTITUTE · 2026 · $418,713

## Abstract

PROJECT SUMMARY – DEVELOPMENTAL FUNDS
The strategic allocation of Developmental Funds has played an indispensable role in advancing the mission of
the Cancer Center and its societal impact during the last Cancer Center Support Grant (CCSG) budget period.
Allocated through a consultative and transparent process that proactively engages all Cancer Center
stakeholders, Developmental Funds fulfill two key Cancer Center goals: (i) support thematic faculty recruitment
in Cancer Center priority areas; and (ii) enable innovative pilot projects for transdisciplinary and multi-investigator
collaboration. First, Developmental Funds allocated during the last five years supported the recruitment of new
Cancer Center leaders, Liang (co-Leader, Molecular and Cellular Oncogenesis Program) and Tian (co-Leader,
Genome Regulation and Cell Signaling Program), as well as Cancer Center members in priority areas of cancer
computational biology, bioinformatics and machine learning (Auslander, Srivastava), viral oncogenesis and
innate immune signaling (Price, Tempera), and the immune tumor microenvironment and associated therapeutic
vulnerabilities (Bertolini, Zhang, Veglia). Second, innovative pilot projects supported by Developmental Funds
led to three, multi-institutional program project grants in Epstein-Barr Virus (EBV)-driven epithelial malignancies
(PI, Lieberman, P01 CA269043-funded); personalized therapy of high-grade serous ovarian cancer (PI, Murphy;
P01 CA288279-under review); and plasticity of therapy-induced neuroendocrine prostate cancer (PI, Languino;
P01 CA298993-under review). As hallmark of the Wistar Cancer Center, Developmental Funds expanded the
trans-institutional partnership with the Helen F. Graham Cancer Center (HFGCC), supporting new tumor-type-
specific collaborations in non-small cell lung cancer, melanoma, and ovarian cancer, and a new, joint initiative in
population health science and breast cancer risk. In aggregate, the return-on-investment of Developmental


## Key facts

- **NIH application ID:** 11333662
- **Project number:** 2P30CA010815-57
- **Recipient organization:** WISTAR INSTITUTE
- **Principal Investigator:** Dario C Altieri
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** CA
- **Fiscal year:** 2026
- **Award amount:** $418,713
- **Award type:** 2
- **Project period:** 1997-04-01T00:00:00 → 2031-02-28T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11333662

## Citation

> US National Institutes of Health, RePORTER application 11333662, Developmental Funds (2P30CA010815-57). Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/grant/nih/11333662. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*